Back to Journals » Cancer Management and Research » Volume 12

Down-Regulation of CCL17 in Cancer-Associated Fibroblasts Inhibits Cell Migration and Invasion of Breast Cancer Through ERK1/2 Pathway [Retraction]

Authors Li J , Yang C, Yang J, Zou L

Received 27 August 2020

Accepted for publication 27 August 2020

Published 8 September 2020 Volume 2020:12 Pages 8115—8116

DOI https://doi.org/10.2147/CMAR.S279114



Li J, Yang C, Yang J, Zou L. Cancer Manag Res.  2019;11:7439– 7453.


The Editor-in-Chief and Publisher of Cancer Management and Research wish to retract the published article. 


The authors contacted the journal to correct images in Figures 4E and 6D however on review it was found more images appeared to be duplicated.


● Figure 3E MCF-7 Migration CAFs+shNC appears duplicated with Figure 6D Migration Vector+rCCL17
● Figure 5C Invasion NFs+CCL17 appears duplicated with Figure 6D Invasion Vector+rCCL17
● Figure 6D Migration DUSP6 appears duplicated with Figure 6D Invasion DUSPS
● Figure 4E bands GAPDH appear duplicated with bands p-ERK ½


The authors were unable to provide a satisfactory explanation for the alleged duplications and could not provide satisfactory raw image data for their western blots. The editor determined the findings of the study were no longer supported and requested for the article to be retracted.


Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.


The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

This retraction relates to this paper

Creative Commons License © 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.